Loading stock data…
Prothena Corporation plc (PRTA)
$9.54-0.28 (-2.85%)
After Hours$9.55+0.01 (+0.10%)· Last close Sep 8
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Prothena Corporation plc in the Healthcare sector is trading at $9.54 with a market capitalization of $466M. Wall Street consensus targets $21.40 (5 analysts), implying a +124.3% move over the next 12 months. The stock is currently 19% below its 52-week high of $11.80, remaining 0.5% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +124.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.01M↓ | $51.08M↑ | $21,000↓ | $2.42M↓ | $4.42M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.69M↓ | $25.79M↑ | -$27.21M↑ | -$39.76M↑ | -$52.01M |
| Net Income | -$18.58M↓ | $32.72M↑ | -$21.59M↑ | -$36.54M↑ | -$125.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$466.14M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.33%
Volume
Today's trading volume
305,057
Recent News
Real Parkinson’s Disease Hope from Jupiter Neurosciences
By Mike Sheikh Parkinson’s Disease has challenged drug developers for generations, but Jupiter Neurosciences (NASDAQ: JUNS) is betting that a streamlined clinical plan can break the stalemate. The market isn’t recognizing the story yet with its paltry market cap of $5.0M, and that disconnect has created a sizable opportunity for investors for a future rerating. […] The post Real Parkinson’s Disease Hope from Jupiter Neurosciences appeared first on ExecEdge.
KMDA or PRTA: Which Is the Better Value Stock Right Now?
KMDA vs. PRTA: Which Stock Is the Better Value Option?
PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
Prothena beat adjusted Q2 loss estimates, reaffirmed 2026 cash-use guidance and highlights partner pipeline progress as a key milestone decision nears.
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of -103.92% and -19.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?